Cargando…

Protective Effects of Higher Exposure to Aspirin and/or Clopidogrel on the Occurrence of Hip Fracture among Diabetic Patients: A Retrospective Cohort Study

Aspirin and clopidogrel are commonly prescribed alone or together among the type 2 diabetes mellitus (T2DM) patients, and both agents could affect bone metabolism. This study aimed at demonstrating the effects of the dosage and the duration of aspirin and/or clopidogrel alone or together on the occu...

Descripción completa

Detalles Bibliográficos
Autores principales: Mao, Jui-Ting, Lai, Jung-Nien, Fu, Yi-Hsiu, Yip, Hei-Tung, Lai, Yen-Chun, Hsu, Chung-Y., Chen, Sung-Hsiung, Kuo, Shu-Jui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9599449/
https://www.ncbi.nlm.nih.gov/pubmed/36289888
http://dx.doi.org/10.3390/biomedicines10102626
_version_ 1784816596748861440
author Mao, Jui-Ting
Lai, Jung-Nien
Fu, Yi-Hsiu
Yip, Hei-Tung
Lai, Yen-Chun
Hsu, Chung-Y.
Chen, Sung-Hsiung
Kuo, Shu-Jui
author_facet Mao, Jui-Ting
Lai, Jung-Nien
Fu, Yi-Hsiu
Yip, Hei-Tung
Lai, Yen-Chun
Hsu, Chung-Y.
Chen, Sung-Hsiung
Kuo, Shu-Jui
author_sort Mao, Jui-Ting
collection PubMed
description Aspirin and clopidogrel are commonly prescribed alone or together among the type 2 diabetes mellitus (T2DM) patients, and both agents could affect bone metabolism. This study aimed at demonstrating the effects of the dosage and the duration of aspirin and/or clopidogrel alone or together on the occurrence of hip fracture among T2DM patients. We chose the patients newly diagnosed with T2DM and divided them into four subgroups which are under aspirin monotherapy (78,522 patients), clopidogrel monotherapy (12,752 patients), dual therapy (7209 patients), and patients not taking antiplatelet drugs (401,686 patients). We found that only higher dosage (>360 cumulative daily defined dose (cDDD)) and longer duration (≥3 years) of antiplatelet agents could be associated with lower fracture risk. Compared with the subjects taking <1-year dual agents, the risk of hip fracture was 0.38-fold for the patients taking ≥3-year dual agents. Lower dosage (28–179 cDDD) and shorter duration (1~2 years) could even be associated with higher fracture risk. Overall, the best regimen to fend off the hip fracture was the use of aspirin and clopidogrel for ≥3 years.
format Online
Article
Text
id pubmed-9599449
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-95994492022-10-27 Protective Effects of Higher Exposure to Aspirin and/or Clopidogrel on the Occurrence of Hip Fracture among Diabetic Patients: A Retrospective Cohort Study Mao, Jui-Ting Lai, Jung-Nien Fu, Yi-Hsiu Yip, Hei-Tung Lai, Yen-Chun Hsu, Chung-Y. Chen, Sung-Hsiung Kuo, Shu-Jui Biomedicines Article Aspirin and clopidogrel are commonly prescribed alone or together among the type 2 diabetes mellitus (T2DM) patients, and both agents could affect bone metabolism. This study aimed at demonstrating the effects of the dosage and the duration of aspirin and/or clopidogrel alone or together on the occurrence of hip fracture among T2DM patients. We chose the patients newly diagnosed with T2DM and divided them into four subgroups which are under aspirin monotherapy (78,522 patients), clopidogrel monotherapy (12,752 patients), dual therapy (7209 patients), and patients not taking antiplatelet drugs (401,686 patients). We found that only higher dosage (>360 cumulative daily defined dose (cDDD)) and longer duration (≥3 years) of antiplatelet agents could be associated with lower fracture risk. Compared with the subjects taking <1-year dual agents, the risk of hip fracture was 0.38-fold for the patients taking ≥3-year dual agents. Lower dosage (28–179 cDDD) and shorter duration (1~2 years) could even be associated with higher fracture risk. Overall, the best regimen to fend off the hip fracture was the use of aspirin and clopidogrel for ≥3 years. MDPI 2022-10-19 /pmc/articles/PMC9599449/ /pubmed/36289888 http://dx.doi.org/10.3390/biomedicines10102626 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Mao, Jui-Ting
Lai, Jung-Nien
Fu, Yi-Hsiu
Yip, Hei-Tung
Lai, Yen-Chun
Hsu, Chung-Y.
Chen, Sung-Hsiung
Kuo, Shu-Jui
Protective Effects of Higher Exposure to Aspirin and/or Clopidogrel on the Occurrence of Hip Fracture among Diabetic Patients: A Retrospective Cohort Study
title Protective Effects of Higher Exposure to Aspirin and/or Clopidogrel on the Occurrence of Hip Fracture among Diabetic Patients: A Retrospective Cohort Study
title_full Protective Effects of Higher Exposure to Aspirin and/or Clopidogrel on the Occurrence of Hip Fracture among Diabetic Patients: A Retrospective Cohort Study
title_fullStr Protective Effects of Higher Exposure to Aspirin and/or Clopidogrel on the Occurrence of Hip Fracture among Diabetic Patients: A Retrospective Cohort Study
title_full_unstemmed Protective Effects of Higher Exposure to Aspirin and/or Clopidogrel on the Occurrence of Hip Fracture among Diabetic Patients: A Retrospective Cohort Study
title_short Protective Effects of Higher Exposure to Aspirin and/or Clopidogrel on the Occurrence of Hip Fracture among Diabetic Patients: A Retrospective Cohort Study
title_sort protective effects of higher exposure to aspirin and/or clopidogrel on the occurrence of hip fracture among diabetic patients: a retrospective cohort study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9599449/
https://www.ncbi.nlm.nih.gov/pubmed/36289888
http://dx.doi.org/10.3390/biomedicines10102626
work_keys_str_mv AT maojuiting protectiveeffectsofhigherexposuretoaspirinandorclopidogrelontheoccurrenceofhipfractureamongdiabeticpatientsaretrospectivecohortstudy
AT laijungnien protectiveeffectsofhigherexposuretoaspirinandorclopidogrelontheoccurrenceofhipfractureamongdiabeticpatientsaretrospectivecohortstudy
AT fuyihsiu protectiveeffectsofhigherexposuretoaspirinandorclopidogrelontheoccurrenceofhipfractureamongdiabeticpatientsaretrospectivecohortstudy
AT yipheitung protectiveeffectsofhigherexposuretoaspirinandorclopidogrelontheoccurrenceofhipfractureamongdiabeticpatientsaretrospectivecohortstudy
AT laiyenchun protectiveeffectsofhigherexposuretoaspirinandorclopidogrelontheoccurrenceofhipfractureamongdiabeticpatientsaretrospectivecohortstudy
AT hsuchungy protectiveeffectsofhigherexposuretoaspirinandorclopidogrelontheoccurrenceofhipfractureamongdiabeticpatientsaretrospectivecohortstudy
AT chensunghsiung protectiveeffectsofhigherexposuretoaspirinandorclopidogrelontheoccurrenceofhipfractureamongdiabeticpatientsaretrospectivecohortstudy
AT kuoshujui protectiveeffectsofhigherexposuretoaspirinandorclopidogrelontheoccurrenceofhipfractureamongdiabeticpatientsaretrospectivecohortstudy